BURNING ROCK BIOTECH LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.6 USD | -0.78% |
|
-7.65% | -18.28% |
| 02/04 | Earnings Flash (BNR.L) BURNING ROCK BIOTECH Posts FY23 Revenue $75.7M | MT |
| 02/04 | Earnings Flash (BNR.L) BURNING ROCK BIOTECH Posts FY23 Loss $-0.90 | MT |
| Sales 2022 | 56Cr 7.78Cr 647.44Cr | Sales 2023 | 54Cr 7.42Cr 617.78Cr | Capitalization | 70Cr 9.61Cr 800Cr |
|---|---|---|---|---|---|
| Net income 2022 | -97Cr -13Cr -1.12TCr | Net income 2023 | -65Cr -9.03Cr -751.77Cr | EV / Sales 2022 | 1.38 x |
| Net cash position 2022 | 86Cr 12Cr 984.84Cr | Net cash position 2023 | 62Cr 8.51Cr 708.29Cr | EV / Sales 2023 | 0.15 x |
| P/E ratio 2022 |
-1.66
x | P/E ratio 2023 |
-1.03
x | Employees | 786 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 62.79% |
More Fundamentals
* Assessed data
More news
Latest transcript on Burning Rock Biotech Limited
| 1 day | -0.78% | ||
| 1 week | -7.65% | ||
| Current month | +0.65% | ||
| 1 month | -11.63% | ||
| 3 months | -4.89% | ||
| 6 months | -15.56% | ||
| Current year | -18.28% |
1 week
7.59
8.43
1 month
7.288.99
Current year
5.729.99
1 year
5.7229.20
3 years
5.72375.00
5 years
5.72397.50
10 years
5.72397.50
| Managers | Title | Age | Since |
|---|---|---|---|
Simon Wu
FOU | Founder | - | 01/14/01 |
Yu Sheng Han
CEO | Chief Executive Officer | 46 | 01/14/01 |
Leo Li
DFI | Director of Finance/CFO | 40 | 01/19/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Feng Deng
BRD | Director/Board Member | 61 | 01/16/01 |
Yu Sheng Han
CEO | Chief Executive Officer | 46 | 01/14/01 |
Gang Lu
BRD | Director/Board Member | 53 | 01/14/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.64% | 4 M€ | -27.92% | ||
| 0.02% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/24/22 | 7.6 | -0.78% | 13,165 |
| 21/24/21 | 7.66 | -1.54% | 5,963 |
| 20/24/20 | 7.78 | -6.27% | 6,591 |
| 17/24/17 | 8.3 | +3.36% | 6,594 |
| 16/24/16 | 8.03 | -2.43% | 5,845 |
Delayed Quote Nasdaq, May 23, 2024 at 01:30 am IST
More quotes
Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.
Calendar
28/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -18.28% | 7.8Cr | |
| -20.98% | 783.02Cr | |
| +67.01% | 429.02Cr | |
| -0.84% | 257.93Cr | |
| -8.93% | 247.66Cr | |
| -38.69% | 246.25Cr | |
| -10.75% | 184.42Cr | |
| -19.84% | 153.24Cr | |
| -40.24% | 121.74Cr | |
| +16.56% | 120.34Cr |
- Stock Market
- Equities
- BNR Stock
